Skip to main content

Table 2 Unadjusted EQ-VAS and EQ-5D index scores at each study visit

From: Effective osteoporosis treatment with teriparatide is associated with enhanced quality of life in postmenopausal women with osteoporosis: the European Forsteo Observational Study

Visit

Total study population (N = 1561)

Group A

Group B

Group C

Group D

Recent prior fracturea; incident fracture (N = 119)

Recent prior fracturea; no incident fracture (N = 646)

No recent prior fracturea; incident fracture (N = 89)

No recent prior fracturea; no incident fracture (N = 727)

n

 

n

 

n

 

n

 

n

 

EQ-VAS, mean (SD)

Baseline

1558

52.01(22.0)

117

48.4 (22.0)

636

51.4 (21.8)

88

49.3 (21.6)

717

53.5 (22.1)

3 months

1434

59.0 (19.8)

105

54.9 (18.9)

584

59.3 (19.6)

81

55.2 (17.4)

664

59.8 (20.4)

6 months

1401

61.94(20.1)

110

56.1 (17.8)*†

579

63.3 (19.0)

85

53.6 (19.8)‡

627

62.9 (21.0)

12 months

1304

64.5 (21.4)

106

56.5 (20.7)**††

528

65.5 (20.5)

84

57.9 (17.9)‡

586

66.0 (22.4)

18 months

1249

67.5 (21.4)

101

60.6 (20.9)**††

514

68.8 (20.5)

79

57.8 (18.8)‡‡

555

68.9 (22.1)

24 months

1068

67.4 (22.4)

91

58.9 (24.1)**†

416

69.6 (20.9)

71

54.8 (21.0)‡‡

490

68.9 (22.6)

36 months

951

68.7 (22.5)

79

60.1 (23.7)*†

385

70.2 (21.6)

65

57.9 (22.4)‡‡

422

70.7 (22.3)

Endpointb

1513

64.6 (23.1)

116

57.1 (24.3)*†

615

65.5 (22.5)

84

55.7 (22.5)‡‡

698

66.2 (23.2)

EQ-5D index score, median (Q1, Q3)

Baseline

1535

0.59 (0.08,0.73)

116

0.23 (−0.02, 0.67)††

623

0.59 (0.03, 0.73)

86

0.57 (0.17, 0.69)

710

0.59 (0.09, 0.73)

3 months

1409

0.69 (0.52, 0.76)

103

0.62 (0.29, 0.73)*†

577

0.69 (0.52, 0.76)

80

0.62 (0.23, 0.74)

649

0.69 (0.52, 0.80)

6 months

1367

0.69 (0.52, 0.80)

108

0.62 (0.52, 0.71)**††

564

0.69 (0.59, 0.80)

83

0.62 (0.26, 0.73)‡‡

612

0.69 (0.59, 0.80)

12 months

1289

0.69 (0.59, 0.80)

106

0.69 (0.52, 0.76)*††

522

0.69 (0.59, 0.80)

85

0.62 (0.26, 0.73)‡‡

576

0.73 (0.59, 0.85)

18 months

1233

0.73 (0.59, 0.85)

102

0.66 (0.52, 0.74)**††

513

0.73 (0.62, 0.85)

80

0.62 (0.52, 0.76)‡‡

538

0.73 (0.59, 0.85)

24 months

1057

0.73 (0.59, 0.85)

87

0.62 (0.09, 0.73)**††

410

0.73 (0.62, 0.88)

73

0.69 (0.31, 0.80)‡

487

0.73 (0.59, 0.88)

36 months

939

0.73 (0.59, 0.88)

75

0.62 (0.15, 0.76)**††

377

0.76 (0.62, 1.00)

66

0.69 (0.52, 0.80)‡

421

0.76 (0.62, 1.00)

Endpointb

1483

0.69 (0.52, 0.80)

111

0.59 (0.09, 0.76)**††

605

0.69 (0.59, 0.80)

85

0.69 (0.36, 0.76)‡

682

0.73 (0.52, 0.85)

  1. For the EQ-VAS and EQ-5D index scores, a higher score represents a better quality of life.
  2. Teriparatide treatment was initiated at baseline and continued for up to 18 months; other osteoporosis medications were used between 18 and 36 months after teriparatide was discontinued.
  3. aRecent prior fracture within the last 12 months before baseline visit.
  4. bMissing data was handled using the last observation carried forward (LOCF) method.
  5. Between-group comparisons (Wilcoxon rank-sum test; Bonferroni adjusted p-values).
  6. *p < 0.05, ** p < 0.001 for pairwise comparison of group A versus group B.
  7. †p < 0.05, ††p < 0.001 for pairwise comparison of group A versus group D.
  8. ‡p < 0.05, ‡‡p < 0.001 for pairwise comparison of group C versus groups B and D.